Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB90X
- Development stage
- Preclinical
- Lead developer
- Bexson Biomedical
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
BB90X is an intramuscular formulation of the antifibrinolytic small molecule tranexamic acid, currently in development by Bexson Biomedical for hemorrhage control on the battlefield. Designed for use with the AKESO ruggedized on-body wearable delivery device, BB90X aims to provide rapid, reliable intramuscular administration of tranexamic acid to control bleeding in contested environments without requiring intravenous access. Tranexamic acid works by competitively and reversibly binding to plasminogen, preventing its activation to plasmin and subsequent degradation of fibrin clots, thereby stabilizing clots and reducing blood loss.
02
Targets
PLG (Plasminogen)
Beyond the preview
Go deeper on BB90X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB90X.